4 Stocks Dragging The Drugs Industry Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 49 points (0.3%) at 16,344 as of Tuesday, Dec. 24, 2013, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,931 issues advancing vs. 985 declining with 162 unchanged.

The Drugs industry currently sits up 0.5% versus the S&P 500, which is up 0.2%. On the negative front, top decliners within the industry include Actavis ( ACT), down 0.7%, Alexion Pharmaceuticals ( ALXN), down 0.6% and Amgen ( AMGN), down 0.5%.

TheStreet would like to highlight 4 stocks pushing the industry lower today:

4. Isis Pharmaceuticals ( ISIS) is one of the companies pushing the Drugs industry lower today. As of noon trading, Isis Pharmaceuticals is down $0.98 (-2.4%) to $40.70 on light volume. Thus far, 275,809 shares of Isis Pharmaceuticals exchanged hands as compared to its average daily volume of 1.3 million shares. The stock has ranged in price between $40.30-$41.67 after having opened the day at $41.62 as compared to the previous trading day's close of $41.68.

Isis Pharmaceuticals, Inc. engages in the discovery and development of antisense drugs using novel drug discovery platform. Isis Pharmaceuticals has a market cap of $4.8 billion and is part of the health care sector. Shares are up 299.2% year to date as of the close of trading on Monday. Currently there are 3 analysts that rate Isis Pharmaceuticals a buy, 1 analyst rates it a sell, and 3 rate it a hold.

TheStreet Ratings rates Isis Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. Get the full Isis Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Regeneron Pharmaceuticals ( REGN) is down $3.14 (-1.1%) to $274.87 on light volume. Thus far, 147,119 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 769,800 shares. The stock has ranged in price between $273.00-$279.90 after having opened the day at $278.10 as compared to the previous trading day's close of $278.01.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $27.1 billion and is part of the health care sector. Shares are up 62.5% year to date as of the close of trading on Monday. Currently there are 10 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and feeble growth in the company's earnings per share. Get the full Regeneron Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Herbalife ( HLF) is down $1.55 (-1.9%) to $79.26 on average volume. Thus far, 1.1 million shares of Herbalife exchanged hands as compared to its average daily volume of 2.8 million shares. The stock has ranged in price between $78.55-$80.64 after having opened the day at $80.33 as compared to the previous trading day's close of $80.81.

Herbalife Ltd., through its subsidiaries, produces and distributes weight management, healthy meals and snacks, sports and fitness, energy and targeted nutritional products, and personal care products worldwide. Herbalife has a market cap of $8.1 billion and is part of the consumer goods sector. Shares are up 145.3% year to date as of the close of trading on Monday. Currently there are 5 analysts that rate Herbalife a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Herbalife as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, impressive record of earnings per share growth, increase in net income and expanding profit margins. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Herbalife Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Celgene Corporation ( CELG) is down $1.45 (-0.9%) to $166.90 on light volume. Thus far, 494,875 shares of Celgene Corporation exchanged hands as compared to its average daily volume of 2.9 million shares. The stock has ranged in price between $166.04-$168.34 after having opened the day at $167.69 as compared to the previous trading day's close of $168.35.

Celgene Corporation discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe. Celgene Corporation has a market cap of $69.0 billion and is part of the health care sector. Shares are up 113.4% year to date as of the close of trading on Monday. Currently there are 21 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, expanding profit margins, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Celgene Corporation Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 4 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).
null

If you liked this article you might like

Jim Cramer's 'Mad Money' Recap: Here's This Week's Game Plan

Jim Cramer's 'Mad Money' Recap: Here's This Week's Game Plan

Jim Cramer's Top Takeaways: Red Hat, Isis Pharmaceuticals, AstraZeneca, Cummins

Jim Cramer's Top Takeaways: Red Hat, Isis Pharmaceuticals, AstraZeneca, Cummins

Isis Pharmaceuticals Changes Its Name

Isis Pharmaceuticals Changes Its Name

Highlighted Post-Market Laggard: ISIS Pharmaceuticals (ISIS)

Highlighted Post-Market Laggard: ISIS Pharmaceuticals (ISIS)

Jim Cramer's 'Mad Money' Recap: Stocks Gain When Analysts Curb Negativity

Jim Cramer's 'Mad Money' Recap: Stocks Gain When Analysts Curb Negativity